Literature DB >> 7972319

Inhibition of K+ channels and stimulation of insulin secretion by the sulfonylurea, glimepiride, in relation to its membrane binding in pancreatic islets.

M Schwanstecher1, K Mnner, U Panten.   

Abstract

In isolated pancreatic islets of mice, the relationships between free glimepiride concentration and membrane binding or inhibition of ATP-sensitive K+ channels were examined. Microsomal membrane binding and K+ channel inhibition were half-maximal at 0.7 and 0.3 nmol/l glimepiride, respectively. The corresponding concentrations for glibenclamide were 0.4 and 0.6 nmol/l. Administration of glimepiride (10 nmol/l) or glibenclamide (10 nmol/l) to isolated mouse islets perifused with albumin-containing media induced a slow increase in insulin secretion. The kinetics of the secretory responses to glimepiride and glibenclamide were identical. Determination of albumin binding revealed that the free glimepiride and glibenclamide concentrations applied in our investigation were in the range of therapeutic serum concentrations of the free drugs. It is concluded that the effects of glimepiride and glibenclamide are very similar in mouse beta-cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7972319     DOI: 10.1159/000139222

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  3 in total

1.  Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels.

Authors:  D K Song; F M Ashcroft
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 2.  Glimepiride. A review of its use in the management of type 2 diabetes mellitus.

Authors:  H D Langtry; J A Balfour
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

3.  Met receptor inhibitor SU11274 localizes in the endoplasmic reticulum.

Authors:  Edwin J Wiest; Heather Jensen Smith; Michael A Hollingsworth
Journal:  Biochem Biophys Res Commun       Date:  2018-05-19       Impact factor: 3.322

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.